百利天恒，延迟港股上市

Core Viewpoint - The company, Baili Tianheng, has announced a delay in its global offering and will not proceed with the planned public offering originally scheduled for November 7-12, 2024, due to current market conditions [4][5]. Group 1: Delay in Global Offering - The public offering application funds will be fully refunded, with the refund process expected to be completed by November 17, 2024 [4]. - The decision to delay the global offering does not affect the company's current business operations [4]. - The company is carefully evaluating the timeline for the global offering and listing [4]. Group 2: Future Plans and Applications - The company submitted its application for issuance and listing to the Hong Kong Stock Exchange on July 10, 2024, with subsequent applications planned for January 21, 2025, and September 29, 2025 [4]. - The company received confirmation from the China Securities Regulatory Commission regarding its overseas issuance and listing on December 11, 2024 [5]. - A listing hearing was held by the Hong Kong Stock Exchange Listing Committee on December 19, 2024, to review the company's application [5]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 2.066 billion yuan, a year-on-year decrease of 63.52% [6][7]. - The net profit attributable to shareholders was a loss of 495 million yuan [7]. - The company has developed innovative drug research platforms, including HIRE-ADC, GNC, and HIRE-ARC, aiming to enhance cancer treatment through combination therapies [7].